S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Unique BioPharma Opportunity for Accredited Investors (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Unique BioPharma Opportunity for Accredited Investors (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Unique BioPharma Opportunity for Accredited Investors (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Unique BioPharma Opportunity for Accredited Investors (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Unique BioPharma Opportunity for Accredited Investors (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Unique BioPharma Opportunity for Accredited Investors (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Unique BioPharma Opportunity for Accredited Investors (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Unique BioPharma Opportunity for Accredited Investors (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
NASDAQ:RZLT

Rezolute (RZLT) Stock Price, News & Analysis

$1.72
+0.12 (+7.50%)
(As of 02/23/2024 ET)
Today's Range
$1.58
$1.84
50-Day Range
$0.88
$1.72
52-Week Range
$0.72
$2.69
Volume
384,870 shs
Average Volume
251,432 shs
Market Capitalization
$68.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.67

Rezolute MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
403.9% Upside
$8.67 Price Target
Short Interest
Bearish
2.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.32mentions of Rezolute in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
$63,640 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.08) to ($1.13) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.14 out of 5 stars

Medical Sector

347th out of 941 stocks

Pharmaceutical Preparations Industry

155th out of 431 stocks


RZLT stock logo

About Rezolute Stock (NASDAQ:RZLT)

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

RZLT Stock Price History

RZLT Stock News Headlines

AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
HC Wainwright Reiterates "Buy" Rating for Rezolute (NASDAQ:RZLT)
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
Rezolute appoints Daron Evans as CFO
Rezolute GAAP EPS of -$0.28 in-line
Rezolute Reports First Quarter Fiscal 2024 Results
Rezolute Inc RZLT
See More Headlines
Receive RZLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rezolute and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/14/2023
Today
2/23/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RZLT
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.67
High Stock Price Target
$14.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+403.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-51,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.31 per share

Miscellaneous

Free Float
32,413,000
Market Cap
$68.15 million
Optionable
Not Optionable
Beta
1.14
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Nevan Charles Elam J.D. (Age 57)
    Founder, CEO & Acting Chairman of the Board
    Comp: $973.65k
  • Dr. Brian Kenneth Roberts M.D. (Age 49)
    Chief Medical Officer
    Comp: $738.86k
  • Dr. Davelyn Eaves Hood M.B.A.
    M.D., Director and Head of Scientific & Patient Affairs
  • Mr. Michael R. Deperro
    Senior VP & Head of Corporate Development
  • Mr. Michael Covarrubias
    Senior VP & Head of Program & Portfolio Management
  • Mr. Chris Milks
    VP & Head of Finance
  • Dr. Raj Agrawal M.D.
    VP & Head of Ophthalmological Clinical Development
  • Ms. Robyn Sweinhart
    VP & Head of Quality
  • Ms. Erin O'Boyle
    Senior VP & Head of Clinical Operations
  • Ms. Susan Stewart J.D. (Age 63)
    L.L.M., Chief Regulatory Officer














RZLT Stock Analysis - Frequently Asked Questions

Should I buy or sell Rezolute stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rezolute in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RZLT shares.
View RZLT analyst ratings
or view top-rated stocks.

What is Rezolute's stock price target for 2024?

3 Wall Street research analysts have issued 12-month price targets for Rezolute's shares. Their RZLT share price targets range from $5.00 to $14.00. On average, they predict the company's share price to reach $8.67 in the next twelve months. This suggests a possible upside of 403.9% from the stock's current price.
View analysts price targets for RZLT
or view top-rated stocks among Wall Street analysts.

How have RZLT shares performed in 2024?

Rezolute's stock was trading at $0.9925 at the beginning of the year. Since then, RZLT shares have increased by 73.3% and is now trading at $1.72.
View the best growth stocks for 2024 here
.

Are investors shorting Rezolute?

Rezolute saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 848,000 shares, an increase of 30.7% from the January 15th total of 648,800 shares. Based on an average trading volume of 138,400 shares, the short-interest ratio is currently 6.1 days.
View Rezolute's Short Interest
.

When is Rezolute's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our RZLT earnings forecast
.

How were Rezolute's earnings last quarter?

Rezolute, Inc. (NASDAQ:RZLT) released its quarterly earnings results on Thursday, September, 14th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.36) by $0.11.

What other stocks do shareholders of Rezolute own?
Who are Rezolute's major shareholders?

Rezolute's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (25.63%), Vivo Capital LLC (8.18%), Stonepine Capital Management LLC (6.99%), Nantahala Capital Management LLC (3.88%), Citadel Advisors LLC (0.87%) and UBS Group AG (0.55%). Insiders that own company stock include Brian Kenneth Roberts, Daron Evans, Genexine Inc and Gil M Labrucherie.
View institutional ownership trends
.

How do I buy shares of Rezolute?

Shares of RZLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RZLT) was last updated on 2/24/2024 by MarketBeat.com Staff